SI1373503T1 - Nevtroficni dejavniki - Google Patents

Nevtroficni dejavniki

Info

Publication number
SI1373503T1
SI1373503T1 SI200230656T SI200230656T SI1373503T1 SI 1373503 T1 SI1373503 T1 SI 1373503T1 SI 200230656 T SI200230656 T SI 200230656T SI 200230656 T SI200230656 T SI 200230656T SI 1373503 T1 SI1373503 T1 SI 1373503T1
Authority
SI
Slovenia
Prior art keywords
neurotrophic factors
neublastin
polypeptides
methods
antibodies
Prior art date
Application number
SI200230656T
Other languages
English (en)
Slovenian (sl)
Inventor
Dinah Wen Yee Biogen Inc Sah
Teit E Ns Gene A S Johansen
Anthony Rossomando
Original Assignee
Biogen Idec Inc
Nsgene As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Nsgene As filed Critical Biogen Idec Inc
Publication of SI1373503T1 publication Critical patent/SI1373503T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/4756Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
SI200230656T 2001-03-12 2002-03-12 Nevtroficni dejavniki SI1373503T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/804,615 US20020055467A1 (en) 1998-07-06 2001-03-12 Novel neurotrophic factors
EP02706759A EP1373503B1 (en) 2001-03-12 2002-03-12 Neurotrophic factors
PCT/EP2002/002691 WO2002072826A2 (en) 2001-03-12 2002-03-12 Neurotrophic factors

Publications (1)

Publication Number Publication Date
SI1373503T1 true SI1373503T1 (sl) 2008-04-30

Family

ID=25189406

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200230656T SI1373503T1 (sl) 2001-03-12 2002-03-12 Nevtroficni dejavniki
SI200230954T SI1930439T1 (sl) 2001-03-12 2002-03-12 Nevrotrofiäśni faktorji

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200230954T SI1930439T1 (sl) 2001-03-12 2002-03-12 Nevrotrofiäśni faktorji

Country Status (15)

Country Link
US (1) US20020055467A1 (enExample)
EP (2) EP1373503B1 (enExample)
JP (2) JP3738008B2 (enExample)
CN (1) CN1268744C (enExample)
AT (2) ATE378353T1 (enExample)
AU (1) AU2002240943B2 (enExample)
CA (1) CA2440767C (enExample)
CY (1) CY1111750T1 (enExample)
DE (1) DE60223511T2 (enExample)
DK (2) DK1930439T3 (enExample)
ES (2) ES2296899T3 (enExample)
NZ (1) NZ528790A (enExample)
PT (2) PT1373503E (enExample)
SI (2) SI1373503T1 (enExample)
WO (1) WO2002072826A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
KR100773776B1 (ko) * 1998-07-14 2007-11-12 얀센 파마슈티카 엔.브이. 신경친화성 성장 인자
IL156559A0 (en) * 2000-12-22 2004-01-04 Genentech Inc New use of artemin, a member of the gdnf ligand family
US7442370B2 (en) * 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
EP1395279B1 (en) * 2001-03-28 2011-10-05 Biogen Idec MA Inc. Use of neublastin polypeptides for treating neuropathic pain
US7112321B2 (en) * 2001-12-19 2006-09-26 Genzyme Corporation Adeno-associated virus-mediated delivery of GDNF to skeletal muscles
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Jx日鉱日石エネルギー株式会社 潤滑油組成物
BRPI0407170A (pt) * 2003-01-31 2006-02-21 Biogen Idec Inc conjugados de polìmero de neoblastina mutada
CA2864810A1 (en) * 2003-04-18 2004-11-04 Biogen Idec Ma, Inc. Polymer-conjugated glycosylated neublastin
US7601518B2 (en) * 2003-06-10 2009-10-13 Nsgene A/S Secretion of neublastin
US7598059B2 (en) * 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
AU2004283053A1 (en) 2003-10-20 2005-05-06 Nsgene A/S In vivo gene therapy of Parkinson's Disease
AU2005277227B2 (en) 2004-08-19 2011-10-06 Biogen Ma Inc. Refolding transforming growth factor beta family proteins
GEP20115196B (en) * 2004-08-19 2011-04-11 Biogen Idec Inc Neublastin variants
WO2007042040A2 (en) * 2005-10-11 2007-04-19 Ns Gene A/S TREATMENT OF RETINOPATHIES USING GFRα3 AGONISTS
TWI501774B (zh) * 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
US20100056440A1 (en) * 2006-03-01 2010-03-04 Biogen Idec Ma Inc. Compositions and methods for administering gdnf ligand family proteins
AU2008247637B2 (en) 2007-05-01 2013-12-05 Biogen Ma Inc. Compositions and methods for increasing vascularization
WO2009020964A2 (en) * 2007-08-08 2009-02-12 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
US20100247437A1 (en) * 2007-10-01 2010-09-30 Vgx Pharmaceuticals, Llc Materials and methods for the delivery of biomolecules to cells of an organ
EP2621512B1 (en) * 2010-10-01 2016-04-06 NsGene A/S Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
CN112533642A (zh) * 2018-05-17 2021-03-19 赫利世弥斯株式会社 治疗与化疗诱发的周围神经病变相关的神经性疼痛
AU2022278242B2 (en) 2021-05-18 2024-11-14 Ltt Bio-Pharma Co., Ltd. Pharmaceutical composition for treating or preventing disorder associated with administration of anticancer agent

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
TR199802252T2 (xx) 1996-05-08 1999-02-22 Biogen, Inc N�ral ve renal geli�menin uyar�lmas� i�in ret ligand� (RetL)
WO2000073348A2 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US6284540B1 (en) * 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor
EP1137774A2 (en) * 1998-12-09 2001-10-04 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor

Also Published As

Publication number Publication date
JP3738008B2 (ja) 2006-01-25
CA2440767C (en) 2012-05-29
AU2002240943A2 (en) 2002-09-24
ATE509103T1 (de) 2011-05-15
CN1509333A (zh) 2004-06-30
EP1930439B1 (en) 2011-05-11
NZ528790A (en) 2004-06-25
EP1930439A1 (en) 2008-06-11
US20020055467A1 (en) 2002-05-09
WO2002072826A2 (en) 2002-09-19
CA2440767A1 (en) 2002-09-19
DK1930439T3 (da) 2011-08-29
SI1930439T1 (sl) 2011-09-30
DK1373503T3 (da) 2008-03-25
JP2004531242A (ja) 2004-10-14
PT1930439E (pt) 2011-07-25
EP1373503B1 (en) 2007-11-14
PT1373503E (pt) 2008-02-26
CY1111750T1 (el) 2015-10-07
HK1120556A1 (en) 2009-04-03
WO2002072826A3 (en) 2003-04-10
ATE378353T1 (de) 2007-11-15
AU2002240943B2 (en) 2007-05-10
EP1373503A2 (en) 2004-01-02
DE60223511T2 (de) 2008-10-23
DE60223511D1 (de) 2007-12-27
CN1268744C (zh) 2006-08-09
ES2296899T3 (es) 2008-05-01
ES2366610T3 (es) 2011-10-21
JP2005198656A (ja) 2005-07-28

Similar Documents

Publication Publication Date Title
CY1111750T1 (el) Νευροτροφικοι παραγοντες
SI1095140T1 (sl) Nevrotrofični dejavniki
IL161016A (en) Polypeptides capable of ang-2 binding
PT1015585E (pt) Homologos de ligandos de tie
WO2003054152A3 (en) Novel nucleic acids and polypeptides
WO2003025148A3 (en) Novel nucleic acids and polypeptides
WO2003023013A3 (en) Novel nucleic acids and polypeptides
WO2002081731A3 (en) Novel nucleic acids and polypeptides
WO2004009834A3 (en) Novel nucleic acids and secreted polypeptides
WO2003080795A3 (en) Novel nucleic acids and secreted polypeptides
AU2002365269A8 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
WO2007045019A3 (en) Polyoleosins
WO2003025142A3 (en) Novel nucleic acids and secreted polypeptides
WO2003025134A3 (en) mcFP ENCODING NUCLEIC ACIDS, POLYPEPTIDES, ANTIBODIES AND METHODS OF USE THEREOF
WO2002077180A3 (en) Novel nucleic acids and polypeptides
WO1999053091A3 (de) Gdnf-kodierende dna, teile davon und gdnf-varianten
EA200100110A1 (ru) Нейротрофические факторы
WO2001021794A3 (en) Smad associating polypeptides
WO2001057187A3 (en) Novel bone marrow nucleic acids and polypeptides
WO2001088091A3 (en) Novel bone marrow nucleic acids and polypeptides
TW200519206A (en) Methods for producing novel medaka and novel medaka
WO2004039319A3 (en) Novel human polypeptides encoded by polynucleotides